Skip to main content

Table 3 Treatment-related adverse events reported in at least 1 % of total patients

From: A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study

  CT-P13 (n = 302) RP (n = 300) Total CT-P13 + RP (n = 602)
Infusion-related reaction 30 (9.9) 43 (14.3) 73 (12.1)
Latent TB 22 (7.3) 20 (6.7) 42 (7.0)
Upper respiratory tract infection 23 (7.6) 14 (4.7) 37 (6.1)
Abnormal liver function test 22 (7.3) 14 (4.7) 36 (6.0)
Urinary tract infection 9 (3.0) 11 (3.7) 20 (3.3)
Lower respiratory tract infection 10 (3.3) 9 (3.0) 19 (3.2)
Flare in RA activity 7 (2.3) 5 (1.7) 12 (2.0)
Herpes virus infection 3 (1.0) 7 (2.3) 10 (1.7)
Anemia 4 (1.3) 5 (1.7) 9 (1.5)
Headache 4 (1.3) 5 (1.7) 9 (1.5)
Rash 2 (0.7) 4 (1.3) 6 (1.0)
Pyrexia 1 (0.3) 5 (1.7) 6 (1.0)
  1. RA rheumatoid arthritis, RP reference product (i.e. reference infliximab), TB tuberculosis
  2. Data are presented as count (percentage)